PMID- 18186797
OWN - NLM
STAT- MEDLINE
DCOM- 20080403
LR  - 20181113
IS  - 1744-313X (Electronic)
IS  - 1744-3121 (Print)
IS  - 1744-3121 (Linking)
VI  - 35
IP  - 1
DP  - 2008 Feb
TI  - Association of MCP-1 and CCR2 polymorphisms with the risk of late acute rejection 
      after renal transplantation in Korean patients.
PG  - 25-31
LID - 10.1111/j.1744-313X.2007.00725.x [doi]
AB  - Among the factors modulating transplant rejection, chemokines and their 
      respective receptors deserve special attention. Increased expression of monocyte 
      chemoattractant protein-1 (MCP-1) and its corresponding receptor (chemokine 
      receptor-2, CCR2) has been implicated in renal transplant rejection. To determine 
      the impact of the MCP-1-2518G and CCR2-64I genotypes on renal allograft function, 
      167 Korean patients who underwent transplantation over a 25-year period were 
      evaluated. Genomic DNA was genotyped using polymerase chain reaction followed by 
      restriction fragment length polymorphism analysis. Fifty-five (32.9%) patients 
      were homozygous for the MCP-1-2518G polymorphism. Nine (5.4%) patients were 
      homozygous for the CCR2-64I polymorphism. None of the investigated polymorphism 
      showed a significant shift in long-term allograft survival. However, a 
      significant increase was noted for the risk of late acute rejection in recipients 
      who were homozygous for the MCP-1-2518G polymorphism (OR, 2.600; 95% CI, 
      1.125-6.012; P = 0.022). There was also an association between the MCP-1-2518G/G 
      genotype and the number of late acute rejection episodes (P = 0.024). Although 
      there was no difference in the incidence of rejection among recipients stratified 
      by the CCR2-V64I genotype, recipients with the CCR2-V64I GG genotype in 
      combination with the MCP-1-2518G/G genotype had a significantly higher risk of 
      acute or late acute rejection among the receptor-ligand combinations (P = 0.006, 
      P = 0.008, respectively). The MCP-1 variant may be a marker for risk of late 
      acute rejection in Korean patients.
FAU - Kang, S W
AU  - Kang SW
AD  - Department of Nephrology, College of Medicine, Inje University, Busan, South 
      Korea.
FAU - Park, S J
AU  - Park SJ
FAU - Kim, Y W
AU  - Kim YW
FAU - Kim, Y H
AU  - Kim YH
FAU - Sohn, H S
AU  - Sohn HS
FAU - Yoon, Y C
AU  - Yoon YC
FAU - Joo, H
AU  - Joo H
FAU - Jeong, K H
AU  - Jeong KH
FAU - Lee, S H
AU  - Lee SH
FAU - Lee, T W
AU  - Lee TW
FAU - Ihm, C G
AU  - Ihm CG
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Int J Immunogenet
JT  - International journal of immunogenetics
JID - 101232337
RN  - 0 (CCL2 protein, human)
RN  - 0 (CCR2 protein, human)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Receptors, CCR2)
SB  - IM
MH  - Adult
MH  - Analysis of Variance
MH  - Chemokine CCL2/*genetics
MH  - Female
MH  - Graft Rejection/*genetics
MH  - Graft Survival
MH  - Humans
MH  - *Kidney Transplantation
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - *Polymorphism, Genetic
MH  - Receptors, CCR2/*genetics
PMC - PMC2228509
EDAT- 2008/01/12 09:00
MHDA- 2008/04/04 09:00
PMCR- 2008/02/05
CRDT- 2008/01/12 09:00
PHST- 2008/01/12 09:00 [pubmed]
PHST- 2008/04/04 09:00 [medline]
PHST- 2008/01/12 09:00 [entrez]
PHST- 2008/02/05 00:00 [pmc-release]
AID - EJI725 [pii]
AID - 10.1111/j.1744-313X.2007.00725.x [doi]
PST - ppublish
SO  - Int J Immunogenet. 2008 Feb;35(1):25-31. doi: 10.1111/j.1744-313X.2007.00725.x.